Skip to main content

Table 1 Baseline characteristics of patients with rheumatoid arthritis (RA) studied

From: Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study

  Given TNF-α-blocking therapy Controlsa
Characteristic All patients N = 289 Patients with dermatological events N = 72 N = 289
Male sex, no. (%) 89 (31) 20 (28) 110 (38)
Age (yr) at diagnosis, mean (SD) 44.5 (14.7) 43.4 (12.7) 54.6 (14.1)**
RF-positive, no. (%) 249 (87) 68 (94) 205 (71)*
Disease duration (yr) at baseline, median (range) 9.2 (0.1–44.9) 10.3 (0.3–44.9) 6.2 (0.0–12.6)**
DAS28 at baseline, mean (SD) 5.9 (1.1) 6.1 (1.1) 3.6 (1.4)**
ANA-positive at baseline, no. (%)b 112 (50) 33 (49) 118 (41)
Prior DMARDs, median (range) 4 (1–10) 5 (2–8) 1 (0–6)**
Prednisolone at baseline, no. (%) 112 (39) 34 (47) 21 (7)**
  1. aNot given TNF-α-blocking therapy. bANA at start was present in respectively 261 and 67 patients on TNF-α-blocking therapy. *P < 0.001, **P < 0.0001, compared with RA patients on TNF-α-blocking therapy; P < 0.001 compared with RA patients on TNF-α-blocking therapy who experienced no dermatological events. ANA, antinuclear antibody; DAS28, disease activity score based on 28 joints; DMARD, disease-modifying antirheumatic drug; RF, rheumatoid factor; SD, standard deviation; TNF, tumor necrosis factor.